Pathogenic Bone Loss in Rheumatoid Arthritis: Mechanisms and Therapeutic Approaches

Total Page:16

File Type:pdf, Size:1020Kb

Pathogenic Bone Loss in Rheumatoid Arthritis: Mechanisms and Therapeutic Approaches Review Pathogenic bone loss in rheumatoid arthritis: mechanisms and therapeutic approaches Rheumatoid arthritis (RA) is a systemic inflammatory disorder with progressive joint destruction being its hallmark feature. Conventional treatments, such as DMARDs, aim to inhibit the inflammation; however, over the past decade, major advances in our understanding of bone metabolism has given us the ability to directly treat the bone loss in RA. Although modern anti-inflammatory therapies, such as anti-TNF-a treatment, have resulted in a remarkable improvement in the treatment of RA, these treatments do not directly target bone destruction in the joint. The aim of this review is to demonstrate that antiresorptive therapies can prevent structural joint destruction, particularly in the early stages of anti-inflammatory treatment. A number of novel approaches targeting bone resorption are also becoming available. 1 KEYWORDS: anti-inflammatory treatments n antiresorptive treatments n B ligand Melissa D Cantley , n NFATc1 n nuclear factor of activated T cells n osteoclasts receptor activator of Malcolm D Smith2 & nuclear factor n rheumatoid arthritis David R Haynes1† †Author for correspondence: Rheumatoid arthritis (RA) is a systemic inflam- joints in the hands and feet as well as the knees. 1Discipline of Pathology, School matory disorder characterized by destruction of Other synovial joints such as the ankles, hips, of Medical Sciences, University the joint, and this has a major impact on its func- elbows and shoulders are relatively spared of Adelaide, Adelaide, South tion. Progressive joint destruction is the hall- and the spine is rarely affected, apart from the Australia, 5005, Australia mark feature of RA. The disease is characterized atlanto-axial joint in the cervical spine. RA Tel: +61 883 033 180 by joint inflammation, synovial hyperplasia and rarely, if ever, affects distal interphalaengeal Fax: +61 883 034 408 associated destruction of bone and cartilage [1]. joints even though these are synovial joints. [email protected] It is the most common autoimmune disease in It is unclear why RA affects some synovial- 2Rheumatology Research Unit, Australia and currently affects 1% of the world’s lined joints frequently and others rarely or Repatriation General Hospital, population [201]. Despite the prevalence of this never. The primary joints affected include the Adelaide, 5041, South disease, complete understanding of the disease metacarpo-phalangeal, proximal interphalan- Australia, Australia process is still lacking. Most studies have focused geal, mid-carpal, radio-carpal and distal radio- on inflammation in the soft tissues; however, ulnar joints in the hands [2]. In the feet, the research is now focusing on preventing bone and target sites include the metatarso-phalangeal, cartilage destruction. Conventional treatments proximal interphalangeal and the intertarsal for RA aim to inhibit the inflammation; how- joints [2]. The disease results in pain, stiffness ever, over the past decade, major advances in our and swelling of the joints, which impacts on understanding of bone metabolism have enabled their functional capacity. Recurring inflam- us to identify the mechanisms of joint destruc- mation leads to bone and cartilage destruction, tion in RA. This knowledge, in combination affecting the individual’s physical functioning, with the recent development of therapies inhib- and causes both short and long-term morbid- iting bone loss, gives us the ability to directly ity [3]. The synovium is the major target for the treat the bone loss in RA. Although modern inflammatory process where infiltration of the anti-inflammatory therapies have resulted in a tissue occurs with multiple immune cells and remarkable improvement in the treatment of cytokines resulting in tissue inflammation. The RA, this review aims to demonstrate that anti- synovial tissue expands and forms a pannus that resorptive therapies, in combination with mod- invades the bone and cartilage, destroying the ern anti-inflammatory treatments, are needed to tissue as it proceeds [4]. The inflammation of the better prevent structural joint destruction and synovial tissues promotes osteoclastogenesis that disease progression in RA. leads to both focal articular bone erosion at the Rheumatoid arthritis presents clinically as site of pannus formation as well as systemic bone a symmetrical polyarthritis that targets many loss, similar to osteoporosis [4,5]. The invasion of part of joints in the body. RA only affects synovial- inflammatory tissue into the subchondral bone lined joints and predominantly affects peripheral involves many cell types including fibroblasts, 10.2217/IJR.09.42 © 2009 Future Medicine Ltd Int. J. Clin. Rheumatol. (2009) 4(5), 561–582 ISSN 1758-4280 561 Review Cantley, Smith & Haynes Pathogenic bone loss in rheumatoid arthritis: mechanisms & therapeutic approaches Review lymphocytes and monocytes. Monocytes are fracture [17]. It is important to note that other the precursors of osteoclasts that resorb bone factors may contribute to the increased risk of through the acidic disillusion of bone mineral fracture such as the development of osteoporosis and enzymatic destruction of bone matrix [6]. owing to decreased mobility of the RA patient. Resorption of the unmineralized cartilage does not appear to directly involve osteoclasts Mechanisms of disease but seems to be due to proteases that are syn- A major hallmark of inflammatory bone loss thesized by the synovial fibroblasts, neutrophils diseases, such as RA, is enhanced osteo clastic and the chondrocytes [7]. The articular cartilage bone resorption without a corresponding is avascular and nonmineralized, consisting of increase in bone formation. Osteoclasts are the chondrocytes that are embedded in the extra- multinucleated cells derived from the mono- cellular matrix. The extracellular matrix con- cyte/macrophage hematopoietic lineage that sists of a type II collagen network that forms are responsible for resorbing bone [18–20]. The the structural backbone of the matrix along with essential role that osteoclasts play in bone loss other proteins [7]. There is a large amount of in RA has been demonstrated in animal studies proteoglycan in cartilage that binds water and showing that mice without osteoclasts are resis- functions as a mechanical shock absorber [7]. tant to arthritis-induced bone loss [21,22]. The The cartilage damage in RA can be attributed crucial role of osteoclasts in RA bone loss is also to a number of catabolic factors, such as pro- supported by studies of human tissue obtained inflammatory cytokines, aggrecanases, matrix from patients with RA [23–26]. In animal models metalloproteinases and nitric oxide. The syno- of RA, and in human RA, large multinucleated vial fibroblasts express large amounts of matrix- osteoclastic cells resorbing subchondral bone degrading enzymes that invade the articular have been detected at sites of bone erosion in the cartilage resulting in cartilage destruction [7]. joints [27,28]. These osteoclasts form as a result of Many of the factors produced by the inflamed exposure to inflammatory cytokines present in synovium that are involved in the bone destruc- synovial tissue, and understanding this process tion also have an effect on chondrocyte func- is the key to developing treatments for bone loss tioning [8]. Inflammatory cytokines, IL-1 and in RA. Figure 1 demonstrates the inflammatory TNF-a are thought to play a major role in car- cytokines involved in both localized bone loss tilage loss [8]. Many studies have demonstrated within the joint and generalized bone loss. that IL-1 stimulates chondrocytes to increase production of matrix metalloproteinases that nOsteoimmunology degrade the cartilage [9,10]. The involvement of the immune system is fun- While the localized destruction of the joint is damental to the progression of RA. In recent the major focus of treatment, generalized bone decades the involvement of the immune system loss, known as osteopenia, results in a loss of in bone metabolism has become apparent (as bone mineral density (BMD) and elevates the reviewed by Takayanagi et al. [29]). Therefore, risk of osteoporotic fractures in patients with it is not surprising that bone loss in RA appears RA [11]. Clinical studies have evaluated BMD to be controlled by immune factors and cells. in the hands of patients with early RA and found This relationship between the immune system an association between reduction in BMD and and bone metabolism has been termed ‘osteo- disease severity [12,13]. This increased systemic immunology’, and an understanding of osteo- bone loss is attributed to the effects of pro- immunology is vital for developing ways of inflammatory cytokines released from the site preventing bone loss in RA. of synovial inflammation that act systemically and result in a generalized bone loss [14–16]. RA nMacrophage colony has also been demonstrated to have an impact stimulating factor on increasing the risk of fractures as a result of Macrophage colony stimulating factor (M-CSF) the associated generalized bone loss. One study was one of the first factors to be recognized as found an increased risk of fracture, especially of playing an essential role in the process of osteo- the hip (relative risk: 2.0) and the spine (relative clast development. It is normally produced by risk: 2.4), in RA patients compared with age and osteoblasts or bone marrow stromal cells and sex-matched controls. Predictors included a long transmits its signal
Recommended publications
  • Effects of Tofacitinib in Early Arthritis-Induced Bone Loss in an Adjuvant-Induced Arthritis Rat Model
    Effects of tofacitinib in early arthritis-induced bone loss in an adjuvant-induced arthritis rat model Vidal B.1, Cascão R.1, Finnilä MA.2,3, IP. Lopes1, da Glória VG.1, Saarakkala S.2,4, Zioupos P.5, Canhão H.6, Fonseca JE.1,7 1 Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal; 2 Research Unit of Medical Imaging, Physics and Technology, Faculty of Medicine, University of Oulu, Oulu, Finland; 3 Department of Applied Physics, University of Eastern Finland, Kuopio, Finland; 4 Medical Research Center, University of Oulu, Oulu, Finland; 5 Biomechanics Labs, Cranfield Forensic Institute, Cranfield University, DA of the UK; ; 6 EpiDoC Unit, CEDOC, NOVA Medical School, NOVA University, Lisbon, Portugal; 7 Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisbon Academic Medical Centre, Lisbon, Portugal ABSTRACT Rheumatoid arthritis (RA) causes immune mediated local and systemic bone damage. Objectives - The main goal of this work was to analyze, how treatment intervention with tofacitinib prevents the early disturbances on bone structure and mechanics in adjuvant induced arthritis rat model. This is the first study to access the impact of tofacitinib on the systemic bone effects of inflammation. Methods - Fifty Wistar adjuvant-induced arthritis (AIA) rats were randomly housed in experimental groups, as follows: non-arthritic healthy group (N=20), arthritic non-treated (N=20) and 10 animals under tofacitinib treatment. Rats were monitored during 22 days after disease induction for the inflammatory score, ankle perimeter and body weight. Healthy non-arthritic rats were used as controls for comparison. After 22 days of disease progression rats were sacrificed and bone samples were collected for histology, micro computed tomography (micro-CT), 3-point bending and nanoindentation analysis.
    [Show full text]
  • Imaging in Psoriatic Arthritis
    Review Standardizing the monitoring of outcome measures: imaging in psoriatic arthritis The wide spectrum of manifestations of musculoskeletal inflammation in psoriatic arthritis makes standardized assessment of joint damage in psoriatic arthritis a challenge. Assessment of erosions and joint space narrowing on plain radiographs of the hands and feet has remained the benchmark for assessing damage in psoriatic arthritis. The methods used to assess damage have been mostly borrowed from those used in rheumatoid arthritis. Axial joint involvement has not been systematically addressed. Methods to assess spinal disease have been borrowed from those used in ankylosing spondylitis. Both ultrasound and MRI have demonstrated promise in the assessment of psoriatic arthritis. The Outcome Measures in Rheumatology Clinical Trials (OMERACT) group is involved in the development of valid, reliable and feasible methods for assessment of joint involvement in psoriatic arthritis. † KEYWORDS: inflammation n joint damage n MRI n psoriasis n radiography Dafna D Gladman n spondylitis n ultrasonography n validation & Vinod Chandran1 1Psoriatic Arthritis Program, University Health Network, 1E 412, 399 Bathurst Psoriatic arthritis (PsA) is an inflammatory and validates outcome measures in rheumato- Street, Toronto, Ontario, M5T 2S8, musculo skeletal disease associated with psoria- logy, identified several measures that should be Canada †Author for correspondence: sis [1]. Psoriasis is an inflammatory, immune- assessed in patients with PsA [6]. These include University
    [Show full text]
  • Pathogenesis of Bone Erosions in Rheumatoid Arthritis: Not Only
    Rossini et al. J Rheum Dis Treat 2015, 1:2 ISSN: 2469-5726 Journal of Rheumatic Diseases and Treatment Review Article: Open Access Pathogenesis of Bone Erosions in Rheumatoid Arthritis: Not Only Inflammation Maurizio Rossini*, Angelo Fassio, Luca Idolazzi, Ombretta Viapiana, Elena Fracassi, Giovanni Adami, Maria Rosaria Povino, Maria Vitiello and Davide Gatti Department of Medicine, Rheumatology Unit, University of Verona, Italy *Corresponding author: Maurizio Rossini, Department of Medicine, Rheumatology Unit, Policlinico Borgo Roma, Piazzale Scuro, 10, 37134, Verona, Italy, Tel: +390458126770, Fax: +39O458126881, E-mail: [email protected] patients has evidence of focal bone erosions [3]. This phenomenon Abstract is the result of many complex interactions from the cells and the It is a matter of fact that the inflammatory pathogenesis does not cytokines/chemokines system at the synovial and surrounding explain all the skeletal manifestations of Rheumatoid Arthritis tissues level, which culminates with bone destruction. In addition (RA), and the development of bone involvement is sometimes unconnected from the clinical scores of inflammation. On the to the articular crumbling, RA is also associated with a generalized basis of recent studies, we would like to make a point of the new bone loss with a higher prevalence of osteoporosis: RA patients have available evidence about the metabolic pathogenic component double the normal risk of undergoing a femoral fracture [4] and they of bone erosions. We assume that in this process an additional are 4 times more likely to have vertebral fractures [5,6]. Both erosions role could be played by metabolic factors, such as the parathyroid and systemic osteoporosis are related to the unbalance between hormone (PTH), DKK1 (the inhibitor of the Wnt/β catenin pathway) osteoblasts and osteoclasts activity [7,8].
    [Show full text]
  • IL-1Β-Driven Osteoclastogenic T Regulatory Cells Accelerate Bone Erosion in Arthritis
    IL-1β-driven osteoclastogenic T regulatory cells accelerate bone erosion in arthritis Anaïs Levescot, … , Julia F. Charles, Peter A. Nigrovic J Clin Invest. 2021. https://doi.org/10.1172/JCI141008. Research In-Press Preview Autoimmunity Inflammation Graphical abstract Find the latest version: https://jci.me/141008/pdf Osteoclastogenic Tregs IL-1-driven osteoclastogenic T regulatory cells accelerate bone erosion in arthritis Anaïs Levescot1, Margaret H. Chang1,2, Julia Schnell1,3, Nathan Nelson-Maney1, Jing Yan1,4, Marta Martínez-Bonet1, Ricardo Grieshaber-Bouyer1, Pui Y. Lee1,2, Kevin Wei1, Rachel B. Blaustein1, Allyn Morris1, Alexandra Wactor1, Yoichiro Iwakura5, James A. Lederer6, Deepak A. Rao1, Julia F. Charles1,4, and Peter A. Nigrovic1,2 1Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital, Boston MA, USA 2Division of Immunology, Boston Children’s Hospital, Boston MA, USA 3Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany 4Department of Orthopaedic Surgery, Brigham and Women’s Hospital, Boston MA, USA 5Center for Experimental Animal Models, Research Institute for Science & Technology, Tokyo University of Science, Tokyo, Japan 6Department of Surgery, Brigham and Women’s Hospital, Boston MA, USA Correspondence: Peter A. Nigrovic, MD Chief, Division of Immunology Boston Children’s Hospital Karp Family Research Building, Room 10211 One Blackfan Circle Boston, MA 02115 Ph: 617-905-1373 Email: [email protected] All authors declare no related conflicts of interest. 1 Osteoclastogenic Tregs Abstract IL-1 is a pro-inflammatory mediator with roles in innate and adaptive immunity. Here we show that IL-1 contributes to autoimmune arthritis by inducing osteoclastogenic capacity in T regulatory cells (Tregs).
    [Show full text]
  • A Systematic Approach to Differentiating Joint Disorders A
    MedicalContinuing Education PODIATRIC RADIOGRAPHY Objectives After completing this mate- rial the reader shall be able to: 1) List the radiographic criteria for systematically evaluating joints and joint disease. 2) Define: joint effusion, AA SystematicSystematic arthritis mutilans, and en- thesopathy. 3) List common joint dis- ApproachApproach toto orders that are associated with arthritis. 4) Explain the importance DifferentiatingDifferentiating of a lesion (erosion, for exam- ple) having either a well- defined or ill-defined margin. JointJoint DisordersDisorders 5) List target areas in the foot and calcaneus for com- X-rays can be an important mon arthritic disorders. 6) Distinguish between tool in confirming your the joint disorders (based diagnosis. on radiographic findings). Welcome to Podiatry Management’s CME Instructional program. Our journal has been approved as a sponsor of Contin- uing Medical Education by the Council on Podiatric Medical Education. You may enroll: 1) on a per issue basis (at $17.50 per topic) or 2) per year, for the special introductory rate of $109 (you save $66). You may submit the answer sheet, along with the other information requested, via mail, fax, or phone. In the near future, you may be able to submit via the Internet. If you correctly answer seventy (70%) of the questions correctly, you will receive a certificate attesting to your earned cred- its. You will also receive a record of any incorrectly answered questions. If you score less than 70%, you can retake the test at no additional cost. A list of states currently honoring CPME approved credits is listed on pg. 246. Other than those entities cur- rently accepting CPME-approved credit, Podiatry Management cannot guarantee that these CME credits will be acceptable by any state licensing agency, hospital, managed care organization or other entity.
    [Show full text]
  • Denosumab, Cortical Bone and Bone Erosion in Rheumatoid Arthritis
    Correspondence response Ann Rheum Dis: first published as 10.1136/annrheumdis-2016-210027 on 23 August 2016. Downloaded from Response to: ‘Denosumab, cortical bone Correspondence to Professor Tsutomu Takeuchi, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, and bone erosion in rheumatoid arthritis’ 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan; by Rossini et al [email protected] Competing interests None declared. Dear Editor, Provenance and peer review Commissioned; internally peer reviewed. We thank Rossini et al for their comments1 on our recent study on inhibitory effect by denosumab on the progression of bone erosions in Japanese patients with rheumatoid arthritis (RA).2 They addressed their observation from point of view of bone in patient with RA. We think their view brings treatment of RA To cite Takeuchi T, Tanaka Y, Ishiguro N, et al. Ann Rheum Dis 2016;75:e71. closer to treatment of osteoporosis. Accepted 3 August 2016 Activated osteoclasts decrease bone mineral density (BMD) and stimulate bone erosion in patients with RA.3 Receptor activator of nuclear factor kappa-B ligand (RANKL) promotes osteoclast dif- – ferentiation, maturation, and activation.4 7 Denosumab is a fully human monoclonal antibody against RANKL that inhibits osteo- ▸ http://dx.doi.org/10.1136/annrheumdis-2016-210022 clast formation, function, and survival. Denosumab treatment increases BMD in cortical and trabecular bone. In addition, deno- Ann Rheum Dis 2016;75:e71. doi:10.1136/annrheumdis-2016-210027 sumab has been shown to improve cortical bone microstructure in subjects with osteoporosis or low bone mass.89 REFERENCES Increases in lumbar spine and total hip BMD and inhibition 1 Rossini M, Adami G, Viapiana O, et al.
    [Show full text]
  • Association with Its Bone Mineral Density by HR-Pqct in Rheumatoid Arthritis Patients Camille P
    Figueiredo et al. BMC Musculoskeletal Disorders (2021) 22:109 https://doi.org/10.1186/s12891-021-03992-5 RESEARCH ARTICLE Open Access Bone erosion in the 2nd metacarpophalangeal head: association with its bone mineral density by HR-pQCT in rheumatoid arthritis patients Camille P. Figueiredo1* , Mariana O. Perez1, Lucas Peixoto Sales1, Ana Cristina Medeiros2, Valeria F. Caparbo1 and Rosa M. R. Pereira1,2* Abstract Background: Rheumatoid arthritis (RA) is a chronic autoimmune disease depicted by synovial inflammation leading to local and systemic bone loss. The aim of this study was to evaluate by a HR-pQCT (High Resolution Peripheral Quantitative Computed Tomography) study which parameters are associated with volume of bone erosions including bone mineral density (BMD) around erosions (VOI 1 to 4 = volume of interest), BMD of metacarpophalangeal (MCP) head, BMD of radius, presence of osteophytes and joint space width (JSW). Methods: Fifty female RA patients (18–50 years) were enrolled in this study. Demographic and disease-specific data, laboratory inflammatory parameters and handgrip test were performed. All patients underwent HR-pQCT of 2nd and 3rd MCP joints and distal radius, according to established protocols. The volume of bone erosions was evaluated by MIAF (Medical Image Analysis Framework) software. Osteophytes were analyzed by manual method. Results: The mean of age and disease duration were 40.0 ± 6.0 yrs. and 10.8 ± 4.8 yrs., respectively. According to DAS- 28 (Disease Activity Score), 54% (27) of the sample were in remission. However, when SDAI (Simplified Disease Activity Index) was used, only 18% (9) were under remission. The mean of HAQ (Health Assessment Questionnaire), ESR (Erythrocyte sedimentation rate) and CRP (C reactive protein) were 0.9 ± 0.7, 13.9 ± 12.2 mm and 5.6 ± 7.5 mg/mL, respectively.
    [Show full text]
  • The Impact of Rheumatoid Arthritis on Bone Loss: Links to Osteoporosis and Osteopenia
    Open Access Review Article DOI: 10.7759/cureus.17519 The Impact of Rheumatoid Arthritis on Bone Loss: Links to Osteoporosis and Osteopenia Roaa Kareem 1 , Rinky A. Botleroo 2 , Renu Bhandari 1, 3 , Opemipo D. Ogeyingbo 1, 4, 5 , Rowan Ahmed 1 , Mallika Gyawali 1 , Nanditha Venkatesan 6, 1 , Abeer O. Elshaikh 1 1. Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 2. Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA 3. Internal Medicine, Manipal College of Medical Sciences, Kaski, NPL 4. Public Health, Walden University, Minneapolis, USA 5. Internal Medicine, Saint James School of Medicine, Park Ridge, USA 6. Internal Medicine, All India Institute of Medical Sciences, Raipur, IND Corresponding author: Roaa Kareem, [email protected] Abstract Rheumatoid arthritis (RA) is an autoimmune chronic connective tissue disease that produces persistent systemic inflammation, with joint inflammation leading to function loss and joint destruction. Low bone mass causes skeletal bone loss, commonly referred to as osteopenia or osteoporosis. We conducted this literature review to examine the relationship between RA and osteoporosis and the variables contributing to this connection. We used articles from the US National Library of Medicine (PubMed), Google Scholar, Science Direct to access the required information. Eventually, our results concluded that RA could result in local periarticular and generalized bone loss. Many risk factors contribute to this association,
    [Show full text]
  • Hand Erosive Osteoarthritis and Distal Interphalangeal Involvement in Psoriatic Arthritis: the Place of Conservative Therapy
    Journal of Clinical Medicine Review Hand Erosive Osteoarthritis and Distal Interphalangeal Involvement in Psoriatic Arthritis: The Place of Conservative Therapy Elena Poletto 1, Ilaria Tinazzi 2, Antonio Marchetta 2, Nicola Smania 1 and Elena Rossato 3,* 1 Neuromotor and Cognitive Rehabilitation Research Center, Physical and Rehabilitation Medicine Section, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37129 Verona, Italy; [email protected] (E.P.); [email protected] (N.S.) 2 Rheumatology Unit, IRCCS Sacro Cuore Don Calabria, 37024 Negrar, Italy; [email protected] (I.T.); [email protected] (A.M.) 3 Rehabilitation Department, IRCCS Sacro Cuore Don Calabria, 37024 Negrar, Italy * Correspondence: [email protected]; Tel.: +39-045-601-4597 Abstract: Hand erosive osteoarthritis (HEOA) and Psoriatic Arthritis (PsA) with DIP involvement are common diseases affecting the hand. Both of them evolve with a progressive limitation in grip due to limited range of motion of the affected joints and stenosing tenosynovitis. Pharmacological options currently available (corticosteroids and clodronate or Idrossicloroquine) for the treatment of EHOA are mostly symptomatic and currently there are no effective drugs able to modify the course of the disease. In addition, data on drug effectiveness of PsA with DIP involvement are lacking. Conservative therapy should be considered in order to reduce pain and improve hand functionality. There are many studies debating a wide range of non-pharmacological intervention in Citation: Poletto, E.; Tinazzi, I.; the management of HEOA: joint protection program, range of motion and strengthening exercise, Marchetta, A.; Smania, N.; Rossato, E. hand exercise with electromagnetic therapy, application of heat with paraffin wax or balneotherapy, Hand Erosive Osteoarthritis and occupational therapy and education.
    [Show full text]
  • Psoriatic-Arthritis.Pdf
    The new england journal of medicine Review Article Dan L. Longo, M.D., Editor Psoriatic Arthritis Christopher T. Ritchlin, M.D., M.P.H., Robert A. Colbert, M.D., Ph.D., and Dafna D. Gladman, M.D.​​ soriasis is a common skin disease that is associated with multi- From the Allergy, Immunology, and Rheu- ple coexisting conditions. The most prevalent coexisting condition, psoriatic matology Division, University of Roches- ter Medical School, Rochester, NY (C.T.R.); arthritis, develops in up to 30% of patients with psoriasis and is character- the Pediatric Translational Research P Branch, National Institute of Arthritis ized by diverse clinical features, often resulting in delayed diagnosis and treat- ment. Initial reports emphasized a benign course in most patients, but it is now and Musculoskeletal and Skin Diseases, Bethesda, MD (R.A.C.); and the Univer- recognized that psoriatic arthritis often leads to impaired function and a reduced sity Health Network (UHN) Krembil Re- quality of life.1,2 Fortunately, improved knowledge about disease mechanisms has search Institute, the Psoriatic Arthritis catalyzed rapid development of effective targeted therapies for this disease. To help Program, and the Centre for Prognosis Studies in the Rheumatic Diseases — all the clinician recognize and appropriately treat psoriatic arthritis, this review focuses at Toronto Western Hospital, Toronto on epidemiologic and clinical features, pathophysiological characteristics, and (D.D.G.). Address reprint requests to Dr. treatment. Ritchlin at the Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, 601 Elmwood Ave., Box 695, Rochester, NY 14642, or at Psoriatic Arthritis and Spondyloarthritis christopher_ritchlin@ urmc . rochester .
    [Show full text]
  • The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders
    REVIEW published: 21 May 2021 doi: 10.3389/fendo.2021.620920 The Emerging Roles of Endocrine Hormones in Different Arthritic Disorders Eugenia Bertoldo*, Giovanni Adami, Maurizio Rossini, Alessandro Giollo, Giovanni Orsolini, Ombretta Viapiana, Davide Gatti and Angelo Fassio Rheumatology Unit, Department of Medicine, University of Verona, Verona, Italy The relationship between endocrine hormones and the spectrum of rheumatic conditions has long been discussed in the literature, focusing primarily on sexual hormones, such as estrogens, androgens, prolactin (PRL). Estrogens are indeed involved in the pathogenesis of the main inflammatory arthritis thanks to their effects on the immune system, both stimulatory and inhibitory. The PRL system has been discovered in synovial tissue of rheumatoid arthritis (RA) and psoriatic arthritis (PsA), patients and has been propose as a Edited by: new potential therapeutic target. Besides sexual hormones, in the last years scientific Zhong Zheng, interest about the crosstalk of immune system with other class of hormones has grown. University of California, Los Angeles, United States Hormones acting on the bone tissue (i.e. parathyroid hormone, vitamin D) and modulators Reviewed by: of the Wnt pathway (i.e. Dickkopf-1) have been demonstrated to play active role in Sergio Minucci, inflammatory arthritis course, defining a new field of research named osteoimmunology. Università della Campania Luigi Vanvitelli, Italy PTH, which is one of the main determinants of Dkkopf-1, plays a crucial role in bone Miles Douglas Thompson, erosions in RA and a correlation between PTH, Trabecular Bone Score (TBS) and disease ’ Rady Children s Hospital-San Diego, activity has been found in ankylosing spondylitis (AS).
    [Show full text]
  • Arthritis-Related Latest Publications of the Subcommittee Members
    ARTHRITIS-RELATED LATEST PUBLICATIONS OF THE SUBCOMMITTEE MEMBERS NATALIE BOUTRY 1 Boutry N, Paul C, Leroy X, Fredoux D, Migaud H, Cotten A. Rapidly destructive osteoarthritis of the hip: MR imaging findings. AJR 2002; 179: 657-63. 2 Boutry N, Lardé A, Lapègue F, Solau-Gervais E, Flipo RM, Cotten A. Magnetic resonance imaging appearance of the hands and feet in patients with early rheumatoid arthritis. J Rheumatol 2003; 30: 671-79. 3 Boutry N, Lardé A, Demondion X, Cortet B, Cotten H, Cotten A. Metacarpophalangeal joints at US in asymptomatic volunteers and cadaveric specimens. Radiology 2004; 232: 716-24. 4 Boutry N, Flipo RM, Cotten A. MR imaging appearance of rheumatoid arthritis in the foot. Semin Musculoskelet Radiol 2005; 9: 199-209. 5 Boutry N, Hachulla É, Flipo RM, Cortet C, Cotten A. MR imaging findings in hands in early rheumatoid arthritis: comparison with those in systemic lupus erythematosus and primary Sjogren syndrome. Radiology 2005; 236: 593-600. 6 Boutry N, Hachulla É, Zanetti-Musielak C, Morel M, Demondion X, Cotten A. Imaging features of musculoskeletal involvement in systemic sclerosis. Eur Radiol 2007; 17: 1172- 80. 7 Boutry N, Khalil C, Jaspart M, Vieillard MH, Demondion X, Cotten A. Imaging of the hip in patients with rheumatic disorders. Eur J Radiol 2007; 63: 49-58. 8 Boutry N, Morel M, Flipo RM, Demondion X, Cotten A. Early rheumatoid arthritis: a review of MRI and sonographic findings. AJR 2007; 189: 1502-9. 9 Boutry N, do Carmo CC, Flipo RM, Cotten A. Early rheumatoid arthritis and its differentiation from other joint abnormalities.
    [Show full text]